{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"34.5"},{"groupId":"OG003","value":"45.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"}],"units":"Participants"}],"description":"To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule","groups":[{"description":"Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)","id":"OG000","title":"Epoetin Alfa - 40k Weekly"},{"description":"Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG001","title":"Epoetin Alfa - 80k Every 3 Weeks"},{"description":"Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG002","title":"Epoetin Alfa - 120k Every 3 Weeks"},{"description":"Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG003","title":"Darbepoetin Alfa - 500 mcg Every 3 Weeks"}],"paramType":"NUMBER","populationDescription":"All patients that were evaluable per protocol.","reportingStatus":"POSTED","timeFrame":"16 Weeks","title":"The Percentage of Participants With Dose Omitted Due to Hematologic Reason","type":"SECONDARY","unitOfMeasure":"percentage of Participants"}